Skip to main content
Delfa

← All assets

TTYP01

1 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

1

Ongoing

1

Recruiting

1

Completed

0

Sites

1

Countries

1

Endpoints

16

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 16 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
1

Trials by status

Recruiting
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
6
Amyloid biomarkers
4
Safety / tolerability / PK
2
Behavior / neuropsychiatric
1
Tau biomarkers
1
Caregiver / quality of life
1
Other (unclassified)
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 12 of 16 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

3

ADAS-CogCognition

2

Amyloid PET CentiloidAmyloid

1

Phosphorylated tau 217 (p-tau217)Tau

1

Mini-Mental State Examination (MMSE)Cognition

1

ADAS-CogOther

1

Neuropsychiatric Inventory (NPI)Behavior

1

Neurofilament light (NfL)Amyloid

1

Phosphorylated tau 217 (p-tau217)Amyloid

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

1 of 1

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT07252440A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease

TTYP01

Alzheimer’s disease

MCI due to AD / mild AD dementiaPh 2Recruiting1Oct 2028-

Showing 1-1 of 1 trials